Eton Pharmaceuticals (ETON) Net Income towards Common Stockholders (2018 - 2025)

Eton Pharmaceuticals has disclosed Net Income towards Common Stockholders across 8 years of filings, most recently posting $1.5 million for Q4 2025.

• Net Income towards Common Stockholders for Q4 2025 came in at $1.5 million, up 347.99% year-over-year; the trailing twelve-month figure through Dec 2025 was -$4.6 million (down 20.35% YoY), and the FY2025 annual result was -$4.6 million, down 20.35% from the prior year.
• Net Income towards Common Stockholders came in at $1.5 million for Q4 2025 at Eton Pharmaceuticals, up from -$1.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $5.1 million in Q1 2021 to a low of -$6.1 million in Q3 2021.
• The 5-year median for Net Income towards Common Stockholders is -$1.6 million (2022), against an average of -$1.0 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 392.62% in 2023 and tumbled 407.34% in 2025, its largest moves.
• Eton Pharmaceuticals' Net Income towards Common Stockholders stood at $1.0 million in 2021, then declined by 12.22% to $912000.0 in 2022, then tumbled by 347.37% to -$2.3 million in 2023, then soared by 73.49% to -$598000.0 in 2024, then jumped by 347.99% to $1.5 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at $1.5 million (Q4 2025), -$1.9 million (Q3 2025), and -$2.6 million (Q2 2025), per Business Quant data.